Cover Image
Market Research Report

Cervical Cancer - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 232853
Published Content info 1026 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cervical Cancer - Pipeline Review, H2 2018
Published: December 21, 2018 Content info: 1026 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2018, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Symptoms include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Risk factors include human papillomavirus or HPV infections, smoking, weakened immune system, Chlamydia infection, overweight and used of intrauterine device (IUD). Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 7, 59, 47, 3, 41, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 1, 11 and 4 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11026IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Cervical Cancer - Overview
  • Cervical Cancer - Therapeutics Development
  • Cervical Cancer - Therapeutics Assessment
  • Cervical Cancer - Companies Involved in Therapeutics Development
  • Cervical Cancer - Drug Profiles
  • Cervical Cancer - Dormant Projects
  • Cervical Cancer - Discontinued Products
  • Cervical Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cervical Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Cervical Cancer - Pipeline by 3SBio Inc, H2 2018
  • Cervical Cancer - Pipeline by Aadi Bioscience Inc, H2 2018
  • Cervical Cancer - Pipeline by AbbVie Inc, H2 2018
  • Cervical Cancer - Pipeline by Abion Inc, H2 2018
  • Cervical Cancer - Pipeline by Abivax SA, H2 2018
  • Cervical Cancer - Pipeline by Admedus Ltd, H2 2018
  • Cervical Cancer - Pipeline by Advaxis Inc, H2 2018
  • Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Cervical Cancer - Pipeline by Agenus Inc, H2 2018
  • Cervical Cancer - Pipeline by Almac Discovery Ltd, H2 2018
  • Cervical Cancer - Pipeline by amcure GmbH, H2 2018
  • Cervical Cancer - Pipeline by Amgen Inc, H2 2018
  • Cervical Cancer - Pipeline by AntiCancer Inc, H2 2018
  • Cervical Cancer - Pipeline by Asana BioSciences LLC, H2 2018
  • Cervical Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
  • Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2018
  • Cervical Cancer - Pipeline by Bayer AG, H2 2018
  • Cervical Cancer - Pipeline by BeiGene Ltd, H2 2018
  • Cervical Cancer - Pipeline by Biocon Ltd, H2 2018
  • Cervical Cancer - Pipeline by Bioleaders Corp, H2 2018
  • Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2018
  • Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2018
  • Cervical Cancer - Pipeline by Celgene Corp, H2 2018
  • Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2018
  • Cervical Cancer - Pipeline by Cellestia Biotech AG, H2 2018
  • Cervical Cancer - Pipeline by Clovis Oncology Inc, H2 2018
  • Cervical Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2018
  • Cervical Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2018
  • Cervical Cancer - Pipeline by Cue Biopharma Inc, H2 2018
  • Cervical Cancer - Pipeline by CytomX Therapeutics Inc, H2 2018
  • Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H2 2018
  • Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2018
  • Cervical Cancer - Pipeline by Daewon Pharm Co Ltd, H2 2018
  • Cervical Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2018
  • Cervical Cancer - Pipeline by Etubics Corp, H2 2018
  • Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2018
  • Cervical Cancer - Pipeline by EyeGene Inc, H2 2018
  • Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Cervical Cancer - Pipeline by FLX Bio Inc, H2 2018
  • Cervical Cancer - Pipeline by Forbius, H2 2018
  • Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2018
  • Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2018
  • Cervical Cancer - Pipeline by Genentech Inc, H2 2018
  • Cervical Cancer - Pipeline by Genetic Immunity Inc, H2 2018
  • Cervical Cancer - Pipeline by Genexine Inc, H2 2018
  • Cervical Cancer - Pipeline by Genmab A/S, H2 2018
  • Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2018
  • Cervical Cancer - Pipeline by Glycostem Therapeutics BV, H2 2018
  • Cervical Cancer - Pipeline by Gradalis Inc, H2 2018
  • Cervical Cancer - Pipeline by Immunitor Inc, H2 2018
  • Cervical Cancer - Pipeline by Immunomedics Inc, H2 2018
  • Cervical Cancer - Pipeline by IMV Inc, H2 2018
  • Cervical Cancer - Pipeline by Incyte Corp, H2 2018
  • Cervical Cancer - Pipeline by Innate Pharma SA, H2 2018
  • Cervical Cancer - Pipeline by InSight Biopharmaceuticals Ltd, H2 2018
  • Cervical Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2018
  • Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2018
  • Cervical Cancer - Pipeline by JHL Biotech Inc, H2 2018
  • Cervical Cancer - Pipeline by Johnson & Johnson, H2 2018
  • Cervical Cancer - Pipeline by Juno Therapeutics Inc, H2 2018
  • Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2018
  • Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2018

List of Figures

  • Number of Products under Development for Cervical Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018
Back to Top